S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
OTCMKTS:CYDY

CytoDyn News Headlines

$4.05
-0.01 (-0.25 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.02
Now: $4.05
$4.75
50-Day Range
$4.05
MA: $5.35
$7.15
52-Week Range
$0.81
Now: $4.05
$10.01
Volume4.60 million shs
Average Volume4.17 million shs
Market Capitalization$2.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.64

Headlines

CytoDyn (OTCMKTS CYDY) News Headlines Today

Source:
SourceHeadline
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab - Yahoo FinanceCytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab - Yahoo Finance
finance.yahoo.com - March 5 at 6:50 PM
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with LeronlimabCytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
finance.yahoo.com - March 5 at 6:50 PM
CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and BrazilCytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil
finance.yahoo.com - March 5 at 6:50 PM
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - GlobeNewswireCytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - GlobeNewswire
globenewswire.com - March 4 at 1:39 AM
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - Yahoo FinanceCytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - Yahoo Finance
finance.yahoo.com - March 3 at 8:39 PM
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration StatementCytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement
finance.yahoo.com - March 3 at 8:39 PM
CytoDyn (OTCMKTS:CYDY) Trading Down 6.3%CytoDyn (OTCMKTS:CYDY) Trading Down 6.3%
americanbankingnews.com - February 24 at 12:18 AM
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - Yahoo FinanceCytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - Yahoo Finance
finance.yahoo.com - February 23 at 1:27 AM
CytoDyn in discussions with regulators after CD12 data in COVID-19 - Seeking AlphaCytoDyn in discussions with regulators after CD12 data in COVID-19 - Seeking Alpha
seekingalpha.com - February 22 at 3:20 PM
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - GlobeNewswireCytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - GlobeNewswire
globenewswire.com - February 22 at 10:20 AM
CytoDyn: Reliable In All The Wrong Places - Seeking AlphaCytoDyn: Reliable In All The Wrong Places - Seeking Alpha
seekingalpha.com - February 21 at 11:02 PM
CytoDyn investors, executives reach settlement agreement in shareholder suit - Portland Business JournalCytoDyn investors, executives reach settlement agreement in shareholder suit - Portland Business Journal
bizjournals.com - February 1 at 6:44 PM
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - Yahoo FinanceChiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - Yahoo Finance
finance.yahoo.com - January 30 at 12:05 AM
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyns Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - GlobeNewswireChiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn's Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - GlobeNewswire
globenewswire.com - January 29 at 7:05 PM
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP UseChiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use
finance.yahoo.com - January 29 at 7:05 PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Yahoo FinanceONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Yahoo Finance
finance.yahoo.com - January 27 at 5:48 PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - January 27 at 5:48 PM
FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 - PRNewswireFDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 - PRNewswire
prnewswire.com - January 23 at 7:19 AM
CytoDyn Inc (CYDY) Price Targets From AnalystsCytoDyn Inc (CYDY) Price Targets From Analysts
stocknews.com - January 14 at 4:25 PM
REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswireREMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswire
globenewswire.com - January 4 at 8:50 AM
REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different CountriesREMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries
feeds.benzinga.com - January 4 at 6:11 AM
FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyns Phase 3 Trial for Severe-to-Critical COVID-19 Patients - GlobeNewswireFDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients - GlobeNewswire
globenewswire.com - December 31 at 2:41 PM
CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity - GlobeNewswireCytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity - GlobeNewswire
globenewswire.com - December 31 at 4:40 AM
FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 PatientsFDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients
finance.yahoo.com - December 31 at 4:40 AM
CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational AutoimmunityCytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity
finance.yahoo.com - December 31 at 4:40 AM
CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - Yahoo FinanceCytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - Yahoo Finance
finance.yahoo.com - December 30 at 5:19 PM
CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswireCytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswire
globenewswire.com - December 30 at 7:18 AM
CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different CountriesCytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries
finance.yahoo.com - December 30 at 7:18 AM
CytoDyn to amend Phase 3 trial protocol for COVID-19 therapy - Seeking AlphaCytoDyn to amend Phase 3 trial protocol for COVID-19 therapy - Seeking Alpha
seekingalpha.com - December 27 at 6:57 PM
Breakingviews - Pandemic pet boom keeps running for new top dogs - NasdaqBreakingviews - Pandemic pet boom keeps running for new top dogs - Nasdaq
nasdaq.com - December 25 at 1:57 PM
FDA Provides Guidance for Adding an Open-Label Extension to CytoDyns Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded - GlobeNewswireFDA Provides Guidance for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded - GlobeNewswire
globenewswire.com - December 24 at 11:59 PM
FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is UnblindedFDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded
finance.yahoo.com - December 24 at 11:59 PM
FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyns Phase 3 Trial - GlobeNewswireFDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial - GlobeNewswire
globenewswire.com - December 22 at 8:53 AM
FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 TrialFDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial
finance.yahoo.com - December 22 at 8:53 AM
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study - Yahoo FinanceCytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study - Yahoo Finance
finance.yahoo.com - December 16 at 8:29 PM
CytoDyn Inc.: Understanding Leronlimab And HIV - Seeking AlphaCytoDyn Inc.: Understanding Leronlimab And HIV - Seeking Alpha
seekingalpha.com - December 16 at 3:28 PM
CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19 - GlobeNewswireCytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19 - GlobeNewswire
globenewswire.com - December 15 at 6:06 PM
CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19
finance.yahoo.com - December 15 at 6:06 PM
CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab - NasdaqCytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab - Nasdaq
nasdaq.com - December 3 at 11:14 PM
CytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments - GlobeNewswireCytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments - GlobeNewswire
globenewswire.com - December 3 at 6:13 PM
CytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory DevelopmentsCytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments
finance.yahoo.com - December 3 at 6:13 PM
CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH - GlobeNewswireCytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH - GlobeNewswire
globenewswire.com - December 2 at 8:37 AM
CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASHCytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH
finance.yahoo.com - December 2 at 8:37 AM
CytoDyn Inc.CytoDyn Inc.
barrons.com - November 27 at 10:52 PM
CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research - GlobeNewswireCytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research - GlobeNewswire
globenewswire.com - November 23 at 6:43 PM
CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure ResearchCytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research
finance.yahoo.com - November 23 at 6:43 PM
CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial - Seeking AlphaCytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial - Seeking Alpha
seekingalpha.com - November 23 at 8:40 AM
CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year - Yahoo FinanceCytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year - Yahoo Finance
finance.yahoo.com - November 23 at 8:40 AM
CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This YearCytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year
finance.yahoo.com - November 23 at 8:40 AM
CytoDyn Files Protocol With FDA For Phase2 Trial For COVID-19 Patients With Long-Hauler Symptoms - NasdaqCytoDyn Files Protocol With FDA For Phase2 Trial For COVID-19 Patients With Long-Hauler Symptoms - Nasdaq
nasdaq.com - November 17 at 5:51 PM
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.